Drug-to-Polymer Ratio | W = k1t (Ist-order Kinetics) |
(100-w) = ln100-k2t (Zero-order Kinetics) |
(100-w)1/3= 1001/3-k3t (Hixon Crowell Model) |
W = k4t1/2 (Highuchi Model) |
Mt / M∞ = k5 tn (Power Law) |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
k1 ± S D | r1 | k2 ± SD | r2 | k3 ± SD | r3 | k4± SD | r4 | k5 ±SD | r5 | n | |
Diltiazem Hydrochloride and Ethocel 45 Premium CR tablets containing HPMC as Co-excipient | |||||||||||
10: 1 | 4.21±0.231 | 0. 279 | 0.13±0. 078 | 0. 581 | 0. 37±0.078 | 0.689 | 5.34±1.109 | 0.385 | 0. 01±0 .031 | 0. 476 | 0. 061 |
10:2 | 5.35±0.298 | 0.394 | 0.247±0. 092 | 0.516 | 0.441±0.032 | 0.587 | 3.651±0.187 | 0.481 | 0.11±1.341 | 0.584 | 0.073 |
10:3 | 3.325±0.123 | 0.473 | 0.367±0. 108 | 0.487 | 0.623±1.45 | 0.716 | 2.981±1.043 | 0.692 | 0.278±0.918 | 0.491 | 0.089 |
Diltiazem Hydrochloride and Ethocel 45 Premium CR tablets containing CMC-Na as Co-excipient | |||||||||||
10:1 | 4.354±0. 213 | 0. 488 | 0.498±0. 125 | 0. 314 | 0. 67±0. 891 | 0.552 | 3.34±1.108 | 0.489 | 0. 02±0 .451 | 0. 476 | 0. 061 |
10:2 | 3.43±.098 | 0.585 | 0.353±.271 | 0.376 | 0.55±0.09 | 0.663 | 2.651±0.157 | 0.585 | 0.021±2.571 | 0.684 | 0.073 |
10:3 | 4.5±.143 | 0.687 | 0.223±.098 | 0.483 | 0.643±.097 | 0.756 | 3.981±1.163 | 0.491 | 0.078±1.982 | 0.791 | 0.089 |
Diltiazem Hydrochloride and Ethocel 45 Premium CR tablets containing Starch as Co-excipient | |||||||||||
10:1 | 3.123±.09 | 0.393 | 0.152±0.287 | 0.281 | 0. 672±0. 791 | 0.499 | 3.34±2.087 | 0.565 | 0. 03±2 .241 | 0. 375 | 0. 051 |
10:2 | 2.51±.087 | 0.386 | 0.286±0.187 | 0.486 | 0.352±0.19 | 0.677 | 4.651±0.371 | 0.651 | 0.21±4.571 | 0.483 | 0.033 |
10:3 | 4.3±.045 | 0.291 | 0.43±.223 | 0.383 | 0.476±.097 | 0.776 | 2.981±1.432 | 0.442 | 0.08±0.582 | 0.661 | 0.049 |